View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter’s Weekly Newsletter
Keith Flaherty is the director of clinical research at the Massachusetts General Hospital Cancer Center and a previous guest on The Drive. In this episode, Keith first delves into the statistics on cancer's prevalence as we age, underscoring the significance of finding effective treatments and early detection methodologies. He touches on the history of cancer therapeutics and illuminates the notable enhancements in cancer therapy within the last decade that are setting the stage for a promising future. He goes into detail on the potential of immunotherapy and therapies that can combat cancer’s evasive tactics while explaining some of the existing challenges around specificity, cost, and scalability. Additionally, Keith highlights the significant leap in early detection methodologies, namely liquid biopsies, which have the potential not only to determine if a cancer is present in an early stage, but also identify the possible tissue of origin.
We discuss:
Connect With Peter on Twitter, Instagram, Facebook and YouTube
#196 - AMA #32: Exercise, squats, deadlifts, BFR, and TRT
#195 - Freedom, PTSD, war, and life through an evolutionary lens | Sebastian Junger
#194 - How fructose drives metabolic disease | Rick Johnson, M.D.
#193 - AMA #31: Heart rate variability (HRV), alcohol, sleep, and more
#192 - COVID Part 2: Masks, long COVID, boosters, mandates, treatments, and more
#191 - Revolutionizing our understanding of mental illness with optogenetics | Karl Deisseroth M.D., Ph.D.
#190 - Paul Conti, M.D.: How to heal from trauma and break the cycle of shame
#189 - COVID-19: Current state of affairs, Omicron, and a search for the end game
Iñigo San Millán, Ph.D.: Zone 2 Training and Metabolic Health (Ep. #85 Rebroadcast)
#188 - AMA #30: How to Read and Understand Scientific Studies
#187 - Sam Apple: The Warburg Effect—Otto Warburg’s cancer metabolism theory
#186 - Patrick Radden Keefe: The opioid crisis—origin, guilty parties, and the difficult path forward
#185 - Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
Rick Johnson, M.D.: Metabolic Effects of Fructose (Ep. #87 Rebroadcast)
#184 - AMA #29: GLP-1 Agonists—The Future of Treating Obesity?
#183 - James Clear: Building & changing habits
#182 - David Nutt: Psychedelics & Recreational Drugs
#181 - Robert Gatenby, M.D.: Viewing cancer through an evolutionary lens and why this offers a radically different approach to treatment
#180 - AMA #28: All things testosterone and testosterone replacement therapy
#179 - Jeremy Loenneke, Ph.D.: The science of blood flow restriction—benefits, uses, and what it teaches us about the relationship between muscle size and strength
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Huberman Lab
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.